Zydus Launches AI-Powered Glucose Monitors DiasensTM and GlucoLiveTM

Zydus Lifesciences Ltd has launched two new AI-powered Continuous Glucose Monitoring (CGM) devices, DiasensTM and GlucoLiveTM. These devices are part of Zydus’s companion diagnostics portfolio and are designed for patients with diabetes, Chronic Kidney Disease (CKD), and those who have undergone organ transplants. The monitors provide continuous glycaemic surveillance and integrate remote care capabilities. The launch was announced on March 12, 2026, and aims to enhance the management of chronic diseases through advanced technology.

The financial terms related to the launch of DiasensTM and GlucoLiveTM have not been disclosed in the filing. However, the initiative represents a strategic expansion of Zydus’s product offerings in the healthcare technology space. The collaboration with Digicare Health Solutions Private Limited, operating under the brand TatvaCareTM, suggests a shared investment in developing and deploying these advanced monitoring systems. The partnership is expected to facilitate access to the GoodFlipTM app, which supports the devices with AI-powered analytics and integrated care solutions.

The operational scope of the new CGM devices includes real-time glucose monitoring with automatic data streaming to patients’ smartphones every three minutes. This feature eliminates the need for manual scanning, which is common in existing CGM devices. The integration with the GoodFlipTM app allows for AI-driven analysis, trend detection, and the generation of actionable insights. The app also offers personalized diet and exercise coaching, doctor consultations, and a comprehensive medical record vault. A dedicated clinician dashboard supports remote monitoring and early intervention, enhancing the overall care ecosystem.

The market context highlights a significant need for improved glucose monitoring solutions in India, where over 101 million adults live with diabetes. The existing glucose monitoring methods are often episodic, relying on periodic finger-prick tests or laboratory checks. The introduction of DiasensTM and GlucoLiveTM addresses these gaps by providing continuous, real-time data, which is crucial for timely clinical interventions. The devices aim to improve patient outcomes by offering uninterrupted glucose monitoring, especially during overnight periods and emergencies.

The timeline for the implementation of DiasensTM and GlucoLiveTM has not been specified in the filing. However, the launch announcement indicates that the devices are ready for deployment. Zydus Lifesciences Ltd and TatvaCareTM are the primary entities involved in this initiative, with Zydus focusing on the product launch and TatvaCareTM providing the technological infrastructure through the GoodFlipTM app.

TatvaCareTM is a healthcare technology company focused on advancing care delivery through digital innovation. Its integrated portfolio includes solutions like TatvaPracticeTM, an advanced EMR platform, and Tatva.aiTM, a conversational knowledge platform for healthcare professionals. TatvaCareTM aims to enable more connected and efficient patient-centric care across the healthcare ecosystem.

Zydus Lifesciences Ltd is an innovation-led global life sciences company engaged in discovering, developing, manufacturing, and marketing a broad range of healthcare therapies. The company employs over 29,000 people worldwide, including 1,500 scientists in R&D. Zydus is committed to unlocking new possibilities in life sciences through quality healthcare solutions and has introduced several innovative products in the market over the last decade.